Predict your next investment

Private Equity
dbpe.com

See what CB Insights has to offer

Investments

3

Portfolio Exits

2

Funds

27

Service Providers

1

About DB Private Equity

DB Private Equity is amongst the leading alternative investment managers in Europe. DB Private Equity focuses on primary and secondary fund investments as well as direct co-investments for institutional investors and high net worth individuals worldwide. It offers its clients broad diversified or specialized fund-of-funds as well as customized separate managed accounts. In addition, DB Private Equity possesses comprehensive knowledge and expertise in venture capital investments.

DB Private Equity Headquarter Location

Elsa-Brändström-Str. 10-12

Cologne, D-50668,

Germany

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest DB Private Equity News

DeltaMed (Augens Capital e DB) compra il controllo di Bioengineering Laboratories

Jul 30, 2018

DeltaMed (Augens Capital e DB) compra il controllo di Bioengineering Laboratories Delta Med spa, l’ex controllata della quotata Eukedos (ex Arkimedica), ha annunciato nei giorni scorsi l’accordo per l’acquisizione del 77% del capitale di Bioengineering Laboratories srl, al fianco del fondatore, Francesco Greco, che manterrà una quota del 23% nel capitale e verrà nominato amministratore delegato della società  responsabile degli affari medici e scientifici di Delta Med (scarica qui il comunicato stampa ). Bioengineering Laboratories progetta, sviluppa, produce e distribuisce dispositivi medici certificati con particolare riferimento agli accessi vascolari per trattamenti di dialisi acuta, dispositivi medici monouso per urodinamica, cardiochirurgia e critical care e ha di recente ottenuto il prestigioso Sigillo di Eccellenza della Commissione Europea per il progetto Dyalibrid, concepito per innovare il mondo dell’emodialisi con un innovativo accesso vascolare ibrido basato sul materiale Silkothane. Delta Med è controllata dal novembre 2015 da Augens Capital srl (guidato da Marco Mantica), in partnership con il fondo SOF gestito da DB Private Equity (la divisione di private equity di Deutsche Bank) (si veda  altro articolo di BeBeez ). Nell’operazione Delta Med è stata assistita dallo studio legale LMS e da EY per la due-diligence contabile e fiscale. La società è controllata da Augens Holding in partnership con il fondo SOF gestito da DB Private Equity e con il management della società. Fondata nel 1993, Delta Med è uno dei principali produttori mondiali di accessi vascolari periferici ed è inoltre attiva nella produzione e distribuzione in Italia e all’estero di dispositivi medici e accessori monouso per terapie infusionali, pacchi procedurali per sale operatorie e altri prodotti per il settore farmaceutico, ospedaliero e dentale. L’acquisizione del ramo d’azienda di Alfamed si inserisce nelle linee strategiche di sviluppo avviate da Augens Capital, che prevedono la creazione di un grande operatore italiano che disponga di un sofisticato e completo portafoglio di prodotti e tecnologie nell’area degli accessi vascolari. Primo passo di questa strategia è stato l’acquisizione del 100% di Tipromed srl nel gennaio 2017, mentre nel settembre 2017 è stata acquisita la divisione Critical Care di Alfamed (si veda altro articolo di BeBeez ). Con questa terza acquisizione, DeltaMed, sotto la guida dell’amministratore delegato Gabriele Giovanelli,  raggiunge così un fatturato consolidato pro-forma di oltre 25 milioni di euro, di cui più del 50% realizzato nei mercati internazionali, con oltre 100 dipendenti.

DB Private Equity Investments

3 Investments

DB Private Equity has made 3 investments. Their latest investment was in Windeln.de as part of their Series D on May 5, 2014.

CBI Logo

DB Private Equity Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/13/2014

Series D

Windeln.de

$20.55M

Yes

1

6/9/2008

Growth Equity - II

Subscribe to see more

$99M

Subscribe to see more

10

11/29/2006

Growth Equity

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/13/2014

6/9/2008

11/29/2006

Round

Series D

Growth Equity - II

Growth Equity

Company

Windeln.de

Subscribe to see more

Subscribe to see more

Amount

$20.55M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

DB Private Equity Portfolio Exits

2 Portfolio Exits

DB Private Equity has 2 portfolio exits. Their latest portfolio exit was Windeln.de on May 06, 2015.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/6/2015

IPO

$99M

1

11/5/2009

IPO

Subscribe to see more

Subscribe to see more

10

Date

5/6/2015

11/5/2009

Exit

IPO

IPO

Companies

Subscribe to see more

Valuation

$99M

Acquirer

Subscribe to see more

Sources

1

10

DB Private Equity Acquisitions

1 Acquisition

DB Private Equity acquired 1 company. Their latest acquisition was Medi-Globe on March 02, 2016.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

3/2/2016

$99M

Acq - Fin

2

Date

3/2/2016

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Acq - Fin

Sources

2

DB Private Equity Fund History

27 Fund Histories

DB Private Equity has 27 funds, including German Access Fund LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

11/1/2016

German Access Fund LP

Diversified Private Equity

Closed

$275.33M

1

10/21/2014

Secondary Opportunities Fund III (SOF III)

LP Secondaries

Closed

$1,655M

1

4/8/2013

Global Select Fund VI

Fund Of Funds

Open

$53M

1

12/31/2012

DB SOF II

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2011

DB Impact Investment Fund

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

11/1/2016

10/21/2014

4/8/2013

12/31/2012

12/31/2011

Fund

German Access Fund LP

Secondary Opportunities Fund III (SOF III)

Global Select Fund VI

DB SOF II

DB Impact Investment Fund

Fund Type

Diversified Private Equity

LP Secondaries

Fund Of Funds

Subscribe to see more

Subscribe to see more

Status

Closed

Closed

Open

Subscribe to see more

Subscribe to see more

Amount

$275.33M

$1,655M

$53M

$99M

$99M

Sources

1

1

1

10

10

DB Private Equity Service Providers

1 Service Provider

DB Private Equity has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

Partnership data by VentureSource

DB Private Equity Team

12 Team Members

DB Private Equity has 12 team members, including current Managing Director, Andreas Schmidt.

Name

Work History

Title

Status

Andreas Schmidt

Managing Director

Current

Andreas Schmidt

Managing Director

Current

Jan von Bassewitz

Managing Director

Current

Karim Ghanam

Managing Director

Former

Chris Minter

Managing Director

Former

Name

Andreas Schmidt

Andreas Schmidt

Jan von Bassewitz

Karim Ghanam

Chris Minter

Work History

Title

Managing Director

Managing Director

Managing Director

Managing Director

Managing Director

Status

Current

Current

Current

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.